Form 4: Tandem Diabetes CTO Rick Carpenter's RSU Vesting

Tandem Diabetes Care Inc.'s Chief Technology Officer, Rick Carpenter, reported the vesting of restricted stock units and subsequent tax-related share withholdings.

Summary

• Rick Carpenter, Chief Technology Officer (CTO) of Tandem Diabetes Care Inc. (TNDM), reported transactions on February 17, 2026.
• Acquired 1,437 shares of common stock from the vesting of Restricted Stock Units (RSUs) awarded on May 25, 2023.
• Acquired an additional 897 shares of common stock from the vesting of RSUs awarded on May 23, 2024.
• 808 shares were disposed of at $18.95 to satisfy tax withholding obligations related to the first RSU vesting.
• 504 shares were disposed of at $18.95 to satisfy tax withholding obligations related to the second RSU vesting.
• Following these transactions, Carpenter directly beneficially owns 25,274 shares of common stock.
• The RSU awards were granted pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting routine equity compensation and continued alignment of a key executive's interests with shareholders, without indicating any immediate operational or financial concerns.

Positives

• Vesting of Restricted Stock Units indicates continued long-term incentive alignment between the CTO and shareholder interests.
• The acquisition of shares at a $0 exercise price represents a direct increase in the CTO's equity stake in the company.

Negatives

• A portion of vested shares (808 and 504 shares) was withheld to cover tax obligations, reducing the net shares received by the executive.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly RSU vestings, are standard compensation practices across the medical device and biotechnology industries, aligning executive incentives with long-term company performance. This filing reflects routine equity compensation rather than a strategic market move.

Related Party Transactions

• The reported transactions involve the vesting of Restricted Stock Units (RSUs) and subsequent share dispositions for tax withholding, which are standard equity compensation arrangements between the company and its Chief Technology Officer.

Stakeholder Impact

• Shareholders: The vesting and retention of shares by a key executive can be seen as a positive signal of management's continued commitment and alignment with shareholder interests.
• Employees: Reflects the company's ongoing use of equity compensation plans to incentivize and retain key personnel.

Next Steps

• Remaining shares from the May 25, 2023 RSU award will vest in eight equal quarterly installments after May 15, 2024.
• Remaining shares from the May 23, 2024 RSU award will vest in eight equal quarterly installments after May 15, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to equity compensation (RSU vesting and tax withholding). It does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It simply confirms a key executive's continued equity stake and compensation structure.

Keywords

Tandem Diabetes Care, TNDM, Rick Carpenter, Chief Technology Officer, CTO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Compensation, Stock Vesting, Tax Withholding